Project structure and organization

To achieve its objectives HEP-CAR is organized in Work Packages (WPs):


spacer

WP1. Genetic screening to identify deregulated host and tumoural pathways in HCC with different comorbidities.
Task 1.1: Sample Collection (conducted by IDIBAPS in collaboration with UKL-HD)
Task 1.2: Discover genomic alterations in HCC and association of known HCC drivers to co-morbidity and gender
(conducted by IDIBAPS in collaboration with UKL-HD)
Task 1.3: Transcriptomic profiling to assess co-morbidity and gender prevalence in HCC molecular classes and pathway activation
(conducted by IDIBAPS in collaboration with UKL-HD)
Task 1.4: To evaluate host pathways associated with co-morbidities and gender in patients developing HCC
(conducted by IDIBAPS in collaboration with UKL-HD)
Task 1.5: Genetic screening of co-morbidity model systems (conducted by IDIBAPS in collaboration with UKL-HD DKFZ, HMGU, UOXF, INSERM b)

spacer

WP2. Lipidomic analysis of HCC with different co-morbidities / gender
Task 2.1: To define the HCC lipidome and impact of co-morbidities (conducted by BI in collaboration with IDIBAPS, DKFZ, UKL-HD)
Task 2.2: To define the impact of co-morbidity and gender on the plasma lipidome of subjects diagnosed with HCC
(conducted by BI in collaboration with  DKFZ, UKL-HD)
Task 2.3: Lipidomic screening of co-morbidity model systems (conducted by BI in collaboration with DKFZ, HMGU, UOXF, INSERM b)

spacer

WP3. Viral co-morbidities on HCC disease pathways
Task 3.1: To discover the impact of viral infection on the hepatocellular transcriptome
(conducted by UOXF in collaboration with HMGU, INSERM a, INSERM b)
Task 3.1A: HBx and HBc transcriptional activity (conducted by HMGU in collaboration with INSERM a)
Task 3.1B: The role of HIF-1a in the viral-host transcriptome (conducted by UOXF in collaboration with HMGU, INSERM a)
Task 3.2: Impact of viral infection on hepatocellular phosphoproteome (conducted by INSERM b in collaboration with UOXF)
Task 3.3: Impact of viral infection on autotaxin-lysophosphatidic acid signalling pathway (conducted by UOXF in collaboration with HMGU, INSERM b)
Task 3.4: To validate viral-deregulated signalling pathways in HCC of different co-morbidities
(conducted by UOXF in collaboration with HMGU, INSERM a, INSERM b)

spacer

WP4. Immune pathways contributing to HCC progression and control
Task 4.1A: To determine the mechanisms underlying T cell activation in NASH-HCC (conducted by DKFZ in collaboration with UKLFR)
Task 4.1B: To define the role of lipids in activating T cells (conducted by DKFZ in collaboration with BI, UKLFR)
Task 4.2: To phenotype tumour-specific T cell responses in HCC patients with differing co-morbidities (conducted by UKLFR)
Task 4.3: Association of TAA-specific immunity with co-morbidity prior to HCC development (conducted by UKLFR in collaboration with HMGU)
Task 4.4: To identify optimal checkpoint inhibitors for HCC immunotherapy (conducted by UKLFR)

spacer

WP5. Validation of HCC disease pathways and their relevance to co-morbidities and response to therapy
Task 5.1: Select co-morbidity specific and common HCC-signature markers (conducted by UKL-HD in collaboration with DKFZ, IDIBAPS)
Task 5.2A: Validation stage I - human HCC cohorts (conducted by UKL-HD in collaboration with UKLFR, DKFZ, UOXF)
Task 5.2B: Association of HCC signatures with therapy escape (conducted by UKL-HD in collaboration with IDIBAPS)
Task 5.3: Validation stage II – animal models (conducted by DKFZ in collaboration with INSERM b)

spacer

WP6. Management, review and assessment
Task 6.1: To establish an organizational structure and supervision of progress (conducted by UKLFR in collaboration with UOXF, ALTA)
Task 6.2: Administrative management (conducted by UKLFR in collaboration with ALTA)
Task 6.3: Risk evaluation and corrective actions (conducted by UKLFR in collaboration with UOXF)
Task 6.4: Intellectual Property Rights (conducted by UKLFR in collaboration with UOXF, ALTA)

spacer

WP7. Dissemination, communication and exploitation activities
Task 7.1: Dissemination and communication of HEP-CAR results (conducted by all Partners).
Task 7.2: Exploitation of the project results (conducted by all Partners)
Task 7.3: Training (conducted by all Partners)

spacer


organization

 

Project objectives

Back to top